CoChat

Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study

Open access
Morrison, Randall L., Fedgchin, Maggie, Singh, Jaskaran, Van Gerven, Joop, Zuiker, Rob, Lim, Kyoung Soo, van der Ark, Peter, Wajs, Ewa, Xi, Liwen, Zannikos, Peter, Drevets, Wayne C. · 2018 · Psychopharmacology
Cited by 72

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The effect of intranasal esketamine on cognitive functioning in healthy participants is assessed in this study. METHODS: computerized test battery assessed at 1 h predose and 40 min, 2, 4, and 6 h postdose. Secondary measures included the Mental Effort Scale, Karolinska Sleepiness Scale (KSS), and safety. RESULTS: Esketamine was associated with significant cognitive performance impairment at 40 min postdose for all five Cogstate® tests (Detection p = 0.0011, Identification p = 0.0006, One-Card Learning p = 0.0040, One Back p = 0.0017, and Groton Maze Learning Test p < 0.0001) versus placebo. In contrast, performance on these tests did not differ significantly between esketamine and placebo at 2, 4, or 6 h postdose. Secondary outcomes indicated a significant, transient increase from baseline under esketamine versus placebo at 40 min postdose on the Mental Effort Scale and at 40 min and 2 h postdose on KSS (p < 0.0001 for both); however, no significant difference was observed on these outcomes between esketamine and placebo at later timepoints. The most commonly reported adverse events were dizziness (67%), nausea (37.5%), disturbance in attention (29.2%), and fatigue (29.2%); the majority were considered mild in severity. CONCLUSIONS: Esketamine was associated with cognitive performance decline, and greater effort was required to complete the test battery versus placebo at 40 min postdose, which returned to placebo-comparable levels by 2 h postdose. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02094378.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00213-018-4828-5

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 24

  1. Andrade C (2015) Intranasal drug delivery in neuropsychiatry: focus on intranasal ketamine for refractory depression. J Clin Psychiatry 76:628–631 · DOI · Paper page
  2. Bitter C (2011) Transmucosal nasal drug delivery: pharmacokinetics and pharmacodynamics of nasally applied esketamine. Dissertation, University of Basel
  3. Collie A, Maruff P, McStephen M, Darby D (2003) Psychometric issues associated with computerised neuropsychological assessment of concussed athletes. Br J Sports Med 37(6):556–559. https://doi.org/10.1136/bjsm.37.6.556 · DOI
  4. Daly E, Singh J, Fedgchin M, Cooper K, Lim P, Shelton RC, Thase ME, Winokur A, Van Nueten L, Manji H, Drevets WC (2017) Efficacy and safety of intranasal esketamine in treatment-resistant depression: results of a double-blind, doubly-randomized, placebo-controlled study. Am J Psychiatry. In press
  5. Diamond PR, Farmery AD, Atkinson S, Haldar J, Williams N, Cowen PJ, Geddes JR, McShane R (2014) Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol 28(6):536–544. https://doi.org/10.1177/0269881114527361 · DOI · Paper page
  6. Diaz JH (1997) Intranasal ketamine preinduction of paediatric outpatients. Paediatr Anaesth 7(4):273–278. https://doi.org/10.1046/j.1460-9592.1997.d01-93.x · DOI
  7. Himmelseher S, Pfenninger E (1998) The clinical use of S-(+)-ketamine--a determination of its place. Anasthesiol Intensivmed Notfallmed Schmerzther 33(12):764–770. https://doi.org/10.1055/s-2007-994851 · DOI
  8. Louon A, Reddy VG (1994) Nasal midazolam and ketamine for paediatric sedation during computerised tomography. Acta Anaesthesiol Scand 38(3):259–261. https://doi.org/10.1111/j.1399-6576.1994.tb03885.x · DOI
  9. Machado-Vieira R, Salvadore G, Diazgranados N, Zarate CA Jr (2009) Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther 123(2):143–150. https://doi.org/10.1016/j.pharmthera.2009.02.010 · DOI · Paper page
  10. Maruff P, Falleti MG, Collie A, Darby D, McStephen M (2005) Fatigue-related impairment in the speed, accuracy and variability of psychomotor performance: comparison with blood alcohol levels. J Sleep Res 14(1):21–27. https://doi.org/10.1111/j.1365-2869.2004.00438.x · DOI
  11. Mathew SJ, Murrough JW, aan het Rot M, Collins KA, Reich DL, Charney DS (2010) Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol 13(1):71–82. https://doi.org/10.1017/S1461145709000169 · DOI · Paper page
  12. Morgan CJ, Curran HV (2006) Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology 188(4):408–424. https://doi.org/10.1007/s00213-006-0572-3 · DOI · Paper page
  13. Morgan CJ, Muetzelfeldt L, Curran HV (2009) Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction 104(1):77–87. https://doi.org/10.1111/j.1360-0443.2008.02394.x · DOI · Paper page
  14. Murrough JW, Wan LB, Iacoviello B, Collins KA, Solon C, Glicksberg B, Perez AM, Mathew SJ, Charney DS, Iosifescu DV, Burdick KE (2014) Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. Psychopharmacology 231(3):481–488. https://doi.org/10.1007/s00213-013-3255-x · DOI · Paper page
  15. Narendran R, Frankle WG, Keefe R, Gil R, Martinez D, Slifstein M, Kegeles LS, Talbot PS, Huang Y, Hwang DR, Khenissi L, Cooper TB, Laruelle M, Abi-Dargham A (2005) Altered prefrontal dopaminergic function in chronic recreational ketamine users. Am J Psychiatry 162(12):2352–2359. https://doi.org/10.1176/appi.ajp.162.12.2352 · DOI · Paper page
  16. Olver JS, Ignatiadis S, Maruff P, Burrows GD, Norman TR (2008) Quetiapine augmentation in depressed patients with partial response to antidepressants. Hum Psychopharmacol 23(8):653–660. https://doi.org/10.1002/hup.970 · DOI
  17. Pietrzak RH, Olver J, Norman T, Piskulic D, Maruff P, Snyder PJ (2009) A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. J Clin Exp Neuropsychol 31(7):848–859. https://doi.org/10.1080/13803390802592458 · DOI · Paper page
  18. Singh JB, Fedgchin M, Daly E, Xi L, Melman C, De Bruecker G, Tadic A, Sienaert P, Wiegand F, Manji H, Drevets WC (2016) Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry 80(6):424–431. https://doi.org/10.1016/j.biopsych.2015.10.018 · DOI · Paper page
  19. Snyder PJ, Werth J, Giordani B, Caveney AF, Feltner D, Maruff P (2005) A method for determining the magnitude of change across different cognitive functions in clinical trials: the effects of acute administration of two different doses alprazolam. Hum Psychopharmacol 20(4):263–273. https://doi.org/10.1002/hup.692 · DOI · Paper page
  20. Verster JC, van de Loo AJ, Roth T (2015) Mirtazapine as positive control drug in studies examining the effects of antidepressants on driving ability. Eur J Pharmacol 753:252–256. https://doi.org/10.1016/j.ejphar.2014.10.032 · DOI
  21. Weber F, Wulf H, El Saeidi G (2003) Premedication with nasal s-ketamine and midazolam provides good conditions for induction of anesthesia in preschool children. Can J Anaesth 50(5):470–475. https://doi.org/10.1007/BF03021058 · DOI
  22. Weksler N, Ovadia L, Muati G, Stav A (1993) Nasal ketamine for paediatric premedication. Can J Anaesth 40(2):119–121. https://doi.org/10.1007/BF03011307 · DOI
  23. Yanagihara Y, Ohtani M, Kariya S, Uchino K, Hiraishi T, Ashizawa N, Aoyama T, Yamamura Y, Yamada Y, Iga T (2003) Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos 24(1):37–43. https://doi.org/10.1002/bdd.336 · DOI · Paper page
  24. Yoshida T, Ishikawa M, Niitsu T, Nakazato M, Watanabe H, Shiraishi T, Shiina A, Hashimoto T, Kanahara N, Hasegawa T, Enohara M (2012) Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One 7(8):e42676. https://doi.org/10.1371/journal.pone.0042676 · DOI · Paper page

Cited by

See all 72

Metadata

Authors
Morrison, R. L., Fedgchin, M., Singh, J., Van Gerven, J., Zuiker, R., Lim, K. S., van der Ark, P., Wajs, E., Xi, L., Zannikos, P., & Drevets, W. C.
Venue
Psychopharmacology
Published
2018-02-01
Volume
235
Issue
4
Pages
1107-1119
ISSN
  • 0033-3158 (ISSN-L)
  • 1432-2072
OpenAlex
W2793977798
Cited by
72
References
16
FWCI
4.60
Type
journal article
Language
en
Open access
hybrid
Licence
creativecommons.org/licenses/by/4.0 (tdm)
Funders
Janssen Research and Development

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study. https://app.cochat.ai/papers/10.1007/s00213-018-4828-5
The paper
Morrison, R. L., Fedgchin, M., Singh, J., Van Gerven, J., Zuiker, R., Lim, K. S., van der Ark, P., Wajs, E., Xi, L., Zannikos, P., & Drevets, W. C. (2018). Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study. Psychopharmacology. https://doi.org/10.1007/s00213-018-4828-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.